Compare NetApp Inc. (NTAP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Recursion Pharmaceuticals Inc — how do they compare? NetApp Inc. trades at $231.07 (market cap $45.38B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: NetApp Inc. is far larger — about 19.6× Recursion Pharmaceuticals Inc's market cap, and NetApp Inc. pays a 0.9% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NTAP | RXRX | |
|---|---|---|
Market Cap | $45.38B | $2.31B |
Volume | 2,264,311 | 40,478,768 |
Sector | Technology | Health |
52-Week High | $235.84 | $6.79 |
52-Week Low | $94.11 | $2.84 |
Typical Hold Time | 57 Days | 22 Days |
Enterprise Value | $44.34B | $1.83B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $235.84, up 3.23% today, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows bullish technical signals with support near $233 and resistance at $239. Fundamentals are robust with a 70.63% gross margin and 19.19% net income margin, though valuation multiples like the 33.3 P/E are elevated. Recent news highlights strategic AI partnerships and product launches, including Novus storage for AI infrastructure, driving positive sentiment.
Outlook is positive given earnings momentum and AI-driven growth, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is mixed with a $219.30 price target below current levels, suggesting caution despite bullish technicals. Institutional ownership trends and cash flow improvements support stability, but investors should weigh growth prospects against premium pricing.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
